Viatris Inc expected to post earnings of 60 cents a share - Earnings Preview
Viatris Inc expected to post earnings of 60 cents a share - Earnings Preview
Viatris Inc VTRS.OQ VTRS.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2026
The Canonsburg Pennsylvania-based company is expected to report a 2.6% increase in revenue to $3.675 billion from $3.58 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Viatris Inc is for earnings of 60 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Viatris Inc is $18.00, about 2.1% above its last closing price of $17.63
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | 0.50 | 0.50 | 0.59 | Beat | 17.5 |
Dec. 31 2026 | 0.53 | 0.53 | 0.57 | Beat | 6.9 |
Sep. 30 2025 | 0.62 | 0.62 | 0.67 | Beat | 7.9 |
Jun. 30 2025 | 0.56 | 0.56 | 0.62 | Beat | 11.6 |
Mar. 31 2025 | 0.48 | 0.49 | 0.50 | Beat | 2.1 |
Dec. 31 2024 | 0.57 | 0.57 | 0.54 | Missed | -5.4 |
Sep. 30 2024 | 0.68 | 0.68 | 0.75 | Beat | 10.9 |
Jun. 30 2024 | 0.68 | 0.68 | 0.69 | Beat | 1.7 |
This summary was machine generated August 4 at 14:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal